Maximum-tolerated dose, toxicity, and efficacy of (131) I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.

GL DeNardo, SJ DeNardo, DS Goldstein… - Journal of Clinical …, 1998 - ascopubs.org
PURPOSE Lym-1, a monoclonal antibody that preferentially targets malignant lymphocytes,
has induced remissions in patients with non-Hodgkin's lymphoma (NHL) when labeled with …

[PDF][PDF] A Clinical trial of radioimmunotherapy with 67Cu-21T-BAT-Lym-1 for non-Hodgkin's lymphoma

…, S Shen, A Yuan, DS Goldstein… - Journal of Nuclear …, 1999 - Soc Nuclear Med
Resufts: 67Cu-2lT-BAT-Lym-1providedgoodimagingof NHL and favorable radiation dosimetry.
The mean radiation ratios of tumor to body and tumor to marrow were 28: 1 and 15: 1, …

[PDF][PDF] 67Cu-21T-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma

…, LA Kroger, DA DeNardo, DS Goldstein… - Journal of Nuclear …, 1999 - Soc Nuclear Med
StudyDesign Eleven patients with histologically documented lymphoma of immunophenotypical
B-cell type with measurable lymphomatous disease, including at least one lesion of 2 …

Low-dose, Fractionated Radioimmunotherapy for B-cell Malignancies using 131I-LYM-1 Antibody

…, SJ DeNardo, KR Lamborn, DS Goldstein… - Cancer biotherapy & …, 1998 - liebertpub.com
Purpose: This trial was conducted to assess the toxicity and efficacy ofI31I-Lym-l in patients
with either malignantB-cell non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (…

High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170 …

…, RT O'Donnell, A Yuan, S Shen, DS Goldstein… - Clinical cancer …, 2005 - AACR
Purpose: Although radioimmunotherapy alone is effective in lymphoma, its application to
solid tumors will likely require a combined modality approach. In these phase I studies, …

Increased survival associated with radiolabeled lym‐1 therapy for non‐hodgkin's lymphoma and chronic lymphocytic leukemia

…, KR Lamborn, DS Goldstein… - … Journal of the …, 1997 - Wiley Online Library
BACKGROUND Because most patients with advanced non‐Hodgkin's lymphoma (NHL) and
chronic lymphocytic leukemia (CLL) respond to radioimmunotherapy (RIT), the study was …

Radioimmunotherapy with 111In/90Y-2IT-BAD-m170 for Metastatic Prostate Cancer

…, CM Richman, PN Lara, IJ Griffith, DS Goldstein… - Clinical cancer …, 2001 - AACR
Purpose: Over 31,000 Americans die of androgen-independent metastatic prostate cancer
each year. New strategies that do not involve hormonal manipulation but instead recognize …

Are radiometal-labeled antibodies better than iodine-131–labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67–, iodine-131–, and yttrium …

…, DL Kukis, CF Meares, DS Goldstein, S Shen - Clinical Lymphoma, 2000 - Elsevier
Radioimmunotherapy using radiolabeled monoclonal antibodies against tumor-associated
antigens has been efficacious, particularly in the treatment of radiosensitive malignancies …

A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.

…, SJ Denardo, T Wun, DL Kukis, DS Goldstein… - Anticancer …, 2000 - europepmc.org
Background Prior clinical trials proved that all histologic grades of chemotherapy-resistant B-cell
non-Hodgkin's lymphoma (NHL) could respond to radio-immunotherapy (RIT) with 131I-…

67Copper-2-Iminothiolane-6-[p-(Bromoacetamido)benzyl]-TETA-Lym-1 for Radioimmunotherapy of Non-Hodgkin's Lymphoma

…, KR Lamborn, S Shen, A Yuan, DS Goldstein… - Clinical cancer …, 1999 - AACR
Copper-67 ( 67 Cu) has ideal properties for radioimmunotherapy. The 62-h half-life is similar
to the residence time of antibodies in tumor, and the therapeutic β emission of 67 Cu is …